These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 16624686)

  • 1. Appropriateness of spironolactone prescribing in heart failure patients: a population-based study.
    Ko DT; Juurlink DN; Mamdani MM; You JJ; Wang JT; Donovan LR; Tu JV
    J Card Fail; 2006 Apr; 12(3):205-10. PubMed ID: 16624686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001.
    Masoudi FA; Gross CP; Wang Y; Rathore SS; Havranek EP; Foody JM; Krumholz HM
    Circulation; 2005 Jul; 112(1):39-47. PubMed ID: 15983243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.
    Juurlink DN; Mamdani MM; Lee DS; Kopp A; Austin PC; Laupacis A; Redelmeier DA
    N Engl J Med; 2004 Aug; 351(6):543-51. PubMed ID: 15295047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.
    Tamirisa KP; Aaronson KD; Koelling TM
    Am Heart J; 2004 Dec; 148(6):971-8. PubMed ID: 15632880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure.
    Shah KB; Rao K; Sawyer R; Gottlieb SS
    J Am Coll Cardiol; 2005 Sep; 46(5):845-9. PubMed ID: 16139135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of spironolactone in a specialized heart failure clinic.
    Sligl W; McAlister FA; Ezekowitz J; Armstrong PW
    Am J Cardiol; 2004 Aug; 94(4):443-7. PubMed ID: 15325926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spironolactone use in patients with heart failure.
    Trujillo JM; Gonyeau MJ; DiVall MV; Alexander SL
    J Clin Pharm Ther; 2004 Apr; 29(2):165-70. PubMed ID: 15068406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spironolactone use and renal toxicity: population based longitudinal analysis.
    Wei L; Struthers AD; Fahey T; Watson AD; Macdonald TM
    BMJ; 2010 May; 340():c1768. PubMed ID: 20483947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Dangerous hyperkalemia as sequelae of new treatment strategies of heart failure].
    Fuster D; Frey FJ; Ferrari P
    Praxis (Bern 1994); 2000 Dec; 89(49):2073-6. PubMed ID: 11190849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency and predictors of hyperkalemia in patients ≥60 years of age with heart failure undergoing intense medical therapy.
    Muzzarelli S; Maeder MT; Toggweiler S; Rickli H; Nietlispach F; Julius B; Burkard T; Pfisterer ME; Brunner-La Rocca HP;
    Am J Cardiol; 2012 Mar; 109(5):693-8. PubMed ID: 22152974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia.
    Cruz CS; Cruz LS; Domingues GS; Souza CA
    Expert Opin Drug Saf; 2005 Jul; 4(4):677-88. PubMed ID: 16011447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Appropriateness and complications of the use of spironolactone in patients treated in a heart failure clinic.
    Goland S; Naugolny V; Korbut Z; Rozen I; Caspi A; Malnick S
    Eur J Intern Med; 2011 Aug; 22(4):424-7. PubMed ID: 21767763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability of spironolactone in patients with chronic heart failure -- a cautionary message.
    Witham MD; Gillespie ND; Struthers AD
    Br J Clin Pharmacol; 2004 Nov; 58(5):554-7. PubMed ID: 15521905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure.
    Masoudi FA; Havranek EP; Wolfe P; Gross CP; Rathore SS; Steiner JF; Ordin DL; Krumholz HM
    Am Heart J; 2003 Aug; 146(2):250-7. PubMed ID: 12891192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors predicting hyperkalemia in patients with cirrhosis receiving spironolactone.
    Abbas Z; Mumtaz K; Salam A; Jafri W
    J Coll Physicians Surg Pak; 2003 Jul; 13(7):382-4. PubMed ID: 12887837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Slow adoption of helpful heart failure drug. Many people who could benefit from spironolactone aren't getting it.
    Harv Heart Lett; 2010 Feb; 20(6):2. PubMed ID: 20376944
    [No Abstract]   [Full Text] [Related]  

  • 17. Laboratory evaluation of potassium and creatinine among ambulatory patients prescribed spironolactone: are we monitoring for hyperkalemia?
    Raebel MA; McClure DL; Chan KA; Simon SR; Feldstein AC; Lafata JE; Andrade SE; Gunter MJ; Nelson WW; Roblin D; Platt R
    Ann Pharmacother; 2007 Feb; 41(2):193-200. PubMed ID: 17284506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study).
    Vardeny O; Wu DH; Desai A; Rossignol P; Zannad F; Pitt B; Solomon SD;
    J Am Coll Cardiol; 2012 Nov; 60(20):2082-9. PubMed ID: 23083787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of spironolactone use on heart failure mortality: a population-based study.
    Ouzounian M; Hassan A; Cox JL; Johnstone DE; Howlett J;
    J Card Fail; 2007 Apr; 13(3):165-9. PubMed ID: 17448412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in heart failure medications in patients hospitalised and discharged.
    Scherer M; Sobek C; Wetzel D; Koschack J; Kochen MM
    BMC Fam Pract; 2006 Nov; 7():69. PubMed ID: 17123439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.